Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gian Life CareBOM:542918 -4.89%59 Return-on-Tangible-Equity is 2.20% as of Dec. 2025, which is 91% below its 10-year median of 23.78. GuruFocus rates BOM:542918 with a GF Score™ of 59/100 and a GF Value™ of ₹5.87 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Gian Life Care ranks worse than 59.69% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Gian Life Care's annualized net income for the quarter that ended in Dec. 2025 was ₹4.13 Mil. Gian Life Care's average shareholder tangible equity for the quarter that ended in Dec. 2025 was ₹187.67 Mil. Therefore, Gian Life Care's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 2.20%.
The historical rank and industry rank for Gian Life Care's Return-on-Tangible-Equity or its related term are showing as below:
BOM:542918'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -5.92 Med: 23.78 Max: 36.98
Current: -5.92
During the past 7 years, Gian Life Care's highest Return-on-Tangible-Equity was 36.98%. The lowest was -5.92%. And the median was 23.78%.
BOM:542918's Return-on-Tangible-Equity is ranked worse than 59.69% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.07
vs BOM:542918: -5.92
Gian Life Care (BOM:542918) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Gian Life Care Return-on-Tangible-Equity Related Terms
Gian Life Care Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Gian Life Care's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542918 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Gian Life Care's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gian Life Care Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Gian Life Care's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Gian Life Care's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 2.20% mean?
Gian Life Care (BOM:542918) has a Return-on-Tangible-Equity of 2.20% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gian Life Care and its competitors. This is 91% below median its historical median of 23.78. According to the industry distribution chart, Gian Life Care ranks #114 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 59.7%.
Is Gian Life Care's Return-on-Tangible-Equity too high?
Gian Life Care's current Return-on-Tangible-Equity of 2.20% is 91% below median its 10-year median of 23.78. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.07. Gian Life Care's value of 2.20% is 3042.9% above this industry median. Based on the distribution chart, Gian Life Care ranks #114 out of 191 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Gian Life Care has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gian Life Care's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Gian Life Care ranks #114 out of 191 companies for Return-on-Tangible-Equity. This places Gian Life Care in the lower half of its industry. The industry median Return-on-Tangible-Equity is 0.07. Gian Life Care's value of 2.20% is 3042.9% above this benchmark. While the company's 10-year median is 23.78 vs. the industry median of 0.07, Gian Life Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gian Life Care's current Return-on-Tangible-Equity of 2.20% is 3042.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gian Life Care and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gian Life Care's current Return-on-Tangible-Equity is 2.20%, which is 91% below median its own 10-year median of 23.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gian Life Care stock overvalued right now?
Based on GuruFocus' analysis, Gian Life Care (BOM:542918) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹5.87, compared to a current price of ₹4.67 — trading 20.4% below its estimated fair value. The current Return-on-Tangible-Equity is 2.20%, which is 91% below median its 10-year median of 23.78 and 3042.9% above the Medical Diagnostics & Research industry median of 0.07. Gian Life Care's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Gian Life Care (BOM:542918), the current Return-on-Tangible-Equity is 2.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gian Life Care (BOM:542918) Overvalued in 2026?
Based on GuruFocus' analysis, Gian Life Care stock appears to be undervalued.
The current stock price of ₹4.67 is trading 20.4% below its estimated GF Value™ of ₹5.87.
GuruFocus considers Gian Life Care to be Modestly Undervalued.
Key valuation signals for BOM:542918:
Return-on-Tangible-Equity: 2.20% (91% below median its 10-year median of 23.78)
GF Value™: ₹5.87 vs. price of ₹4.67 (20.4% below fair value)
Industry Position: 3042.9% above the Medical Diagnostics & Research median (#114 of 191)
No single metric tells the full story. See the BOM:542918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gian Life Care Ltd is an Indian firm engaged in the business of providing diagnostic and related healthcare tests and services in Kanpur and nearby areas. The company provides a broad range of diagnostic and related healthcare tests and services such as patient diagnosis, prevention, and wellness diagnosis services to its patients and healthcare providers. Its customers include individual patients, hospitals, other healthcare providers, and corporate customers. Substantial revenue accrues from the Pathological Testing Fees. The company has only one operating segment namely, Laboratories Pathological Investigations.
59GF Score
Get the complete analysis for BOM:542918
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542918 has been successfully added to your 
